A panel of experts on renal cell carcinoma discuss patient cases and provide clinical insights on clinical trial data, treatment decisions, and the evolving therapeutic landscape.
EP. 1: Renal Cell Carcinoma: Risk Stratification and Evolving Treatment Landscape
A panel of 4 experts on renal cell carcinoma introduce themselves and discuss IMDC risk stratification criteria and the evolution of the treatment landscape.
Watch
EP. 2: Case 1: Therapeutic Sequencing for Relapsed/Refractory Metastatic Clear Cell RCC
Sumanta Kumar Pal, MD, FASCO, presents the case of a 66-year-old man with metastatic renal cell carcinoma, and the panel provides comprehensive insights on treatment decisions, highlighting the NCCN Guidelines.
Watch
EP. 3: RCC: Treatment Goals in the Third-Line Setting
Focusing on VEGF TKIs available for the treatment of patients with metastatic renal cell carcinoma, the panel discusses the goals of therapy in the third-line setting.
Watch
EP. 4: TIVO-3: Tivozanib vs Sorafenib in Advanced Renal Cell Carcinoma
Sumanta Kumar Pal, MD, FASCO, reviews data from the TIVO-3 study investigating tivozanib in patients with advanced renal cell carcinoma, and the panel offers its impressions on the results.
Watch
EP. 5: Clinical Trials Evaluating Lenvatinib Plus Everolimus in Advanced Renal Cell Carcinoma
The panel discusses the lenvatinib plus everolimus regimen for patients with advanced renal cell carcinoma, highlighting clinical trial data on its efficacy and safety profile.
Watch
EP. 6: LITESPARK-005: Belzutifan in Previously Treated Advanced Clear Cell RCC
Following a review of the LITESPARK-005 trial, experts on renal cell carcinoma discuss the potential role of belzutifan in the treatment algorithm.
Watch
EP. 7: Case 2: A 48-Year-Old Man with Renal Cell Carcinoma
Sumanta Kumar Pal, MD, FASCO, presents the case of a 48-year-old man with renal cell carcinoma, and Rana R. McKay, MD, discusses how she discusses risk of recurrence with patients.
Watch